Screening for hepatitis B carriers: Evidence and policy development in New Zealand

New Zealand Medical Journal

Volumn 112, Issue 1099, 1999, Pages 431-433

  Blakely, Tony ^a   Thornley, Craig N ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; HEALTH CARE POLICY; HEPATITIS B; HUMAN; MASS SCREENING; NEW ZEALAND;

HEALTH POLICY; HEPATITIS B; HEPATITIS B, CHRONIC; HUMANS; MASS SCREENING; NEW ZEALAND;

EID: 0033550098     PISSN: 00288446     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Health Funding Authority. Media release: Hepatitis B screening programme progressing. Wellington: Health Funding Authority; 15 December 1998 .
2. Rt Hon Winston Peters. Media release: Hepatitis B screening programme gets green light, Deputy Prime Minister and Treasurer. 3 July 1998.
3. ESR. Hepatitis B rates continue to decline. NZ Public Health Rep 1995; 2: 69.
4. Working Party on Hepatitis B. Screening and Hepatitis B Infection in New Zealand: Report to the Director-General of health of the Hepatitis B Working Party. Wellington: Ministry of Health; 1994.
5. Blakely T, Bates M, Garrett N et al. The incidence of hepatocellular carcinoma in New Zealand. NZ Med J 1998; 111: 471-4
6. McMahon BJ, Rhoades ER, Heyward WL et al. A comprehensive program to reduce the incidence of hepatitis B virus infection and its sequelae in Alaskan natives. Lancet 1987; 2: 1134-6.
7. Tang Z-Y, Yu Y-Q, Zhou X-D et al. Surgery of small hepatocellular carcinoma: analysis of 144 cases. Cancer 1989; 64: 536-41.
8. Mima S, Sekiya C, Kanagawa H et al. Mass screening for hepatocellular carcinoma: experience in Hokkaido, Japan. J Gastroenterol Hepatol 1994; 9: 361-5.
9. Sherman M, Peltekian K, Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology 1995; 22: 432-8.
10. Lucas C, Milne A, Hopkirk N. Kawerau revisited: hepatitis A and B seroprevalence in 1984 and 1993. NZ Med J 1994; 107: 266-8.
11. Chen H-L, Chang M-H, Ni Y-H et al. Seroepidemiology of hepatitis B virus infection in children: ten years of mass vaccination in Taiwan. JAMA 1996; 276 906-8.
12. Lee C-L, Ko Y-C. Hepatitis B vaccination and hepatocellular carcinoma in Taiwan. Pediatrics 1997; 99: 351-3.
13. Working Party on Hepatitis B. The feasibility of screening for and surveillance of hepatitis B in a single geographic area: reporting to the Director-General of Health of the Working Party on Hepatitis B. Wellington: Ministry of Health; 1996.
14. Wong D, Cheung A, O'Rouke K et al. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: A meta-analysis. Ann Intern Med 1993; 119: 312-23.
15. Tine F, Liberati A, Craxi A et al. Interferon treatment in patients with chronic hepatitis B: a meta-analysis of the published literature. J Hepatol 1993; 18: 154-62.
16. Korenman J, Baker B, Waggoner J et al. Long-term remission of chronic hepatitis B aftern alpha-interferon therapy. Ann Int Med 1991; 114: 629-34.
17. Lai C-L, Chien R-N, Leung N et al. A one year trial of lamuvidine for chronic hepatitis B. N Engl J Med 1998; 339: 61-8.
18. Hoofnagle J, Di Bisceglie A. The treatment of chronic viral hepatitis. Drug Ther 1997; 336: 347-56.
19. Tobias MI, Miller JA, Clements CJ et al. Hepatitis B in New Zealand children: the 1985 national immunisation survey. NZ Med J 1967; 100:203-6.
20. Milne A, Allwood GK, Moyes CD et al. Prevalence of hepatitis B infections in a multiracial New Zealand community. NZ Med J 1985; 98: 529-32.
21. Niederau C, Heintges T, Lange S et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996; 334: 1422-7.
22. International Interferon Hepatocellular Carcinoma Study Group. Effect of interferonalpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. Lancet 1998; 351: 1535-9.
23. Ikeda K, Saitoh S, Suzuki Y et al. Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by hepatitis B virus. Cancer 1998; 82: 827-35.
24. Wanebo H, Vezeridis M. Hepatoma. J Surg One 1993; Suppl 3:40-5.
25. Takenaka K, Yamamoto K, Taketomi A et al. A comparison of the surgical results in patients with hepatitis B versus hepatitis C-related hepatocellular carcinoma. Hepatology 1995; 22:20-4.
26. Farmer D, Rosove M, Shaked A et al. Current treatment modalities for hepatocellular carcinoma. Arm Surg 1994; 219: 23647.
27. Mazzaferro V, Regallia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-9.
28. McMahon B. Early detection of hepatocellular carcinoma (HCC) in HBsAg-positive carriers: a 15 year prospective population-based study in Alaska, abstract for conference. 1998.
29. Stewart-Brown S, Fartner A. Screening could seriously damage your health: Decisions to screen must take account of the social and psychological costs. BMJ 1997; 314: 533-4.
30. North Health. Hepatitis B screening and follow-up programme in defined geographic area/s: Draft planning and discussion document. Auckland: North Health; 1997.
31. Entwhistle M. Presentation to a meeting on 16 October called by the Hepatitis Foundation, Wellington: Health Funding Authority; 16 October 1998.